Loading clinical trials...

Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation

A Two Years Multicentre Study of Genotropin Treatment of Short Prepubertal Children With Intra-Uterine Growth Retardation

NCT01073605•Pfizer

View on ClinicalTrials.gov

Summary

To evaluate the effect of continuous and intermittent administration of Genotonorm on stature in short prepubertal children with intra-uterine growth retardation

Eligibility

Age

3 - 12 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Chronological age (CA) between 3 and 10 for girls
•Chronological age between 3 and 12 for boys
•Height for CA below - 2 SD
•Birth length for CA below -2SD

Exclusion Criteria

•Endocrine disease except well-substituted hypothyroidism
•Sever chronic disease
•Skeletal dysplasia
•Known chromosomal aberration
•Ongoing treatment with steroids
•Known intrauterine infection

Locations (31)

Pfizer Investigational Site

Angers, France, France

Pfizer Investigational Site

Grenoble, France, France

Pfizer Investigational Site

Paris, France, France

Pfizer Investigational Site

Amiens, France

Pfizer Investigational Site

Besançon, France

Pfizer Investigational Site

Bordeaux, France

Pfizer Investigational Site

Bordeaux, France

Pfizer Investigational Site

Boulogne, France

Pfizer Investigational Site

Brest, France

Pfizer Investigational Site

Bron, France

Key Dates

Start Date

July 1, 1993

Primary Completion Date

May 1, 2009

Completion Date

May 1, 2009

Last Updated

November 18, 2010

Enrollment

208

ACTUAL participants

Conditions

Growth DisordersIntrauterine Growth Retardation

Interventions

Genotonorm

DRUG

Genotonorm

DRUG

Genotonorm

DRUG

Early Lung Function Trajectories: Comparison Between Infants With and Without Intrauterine Growth Restriction.

NCT06919757

Intrauterine Growth Retardation (IUGR)Lung Function Tests+2 more

View study

RECRUITING

Impact of Iron Deficiency Anemia on Neurobehavioral and Cognitive Development in Children Aged 6 to 24 Months

NCT06662045

Iron-Deficiency AnemiaNeurobehavioral Manifestations+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 18, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation

Inclusion Criteria

Exclusion Criteria

Early Lung Function Trajectories: Comparison Between Infants With and Without Intrauterine Growth Restriction.

Impact of Iron Deficiency Anemia on Neurobehavioral and Cognitive Development in Children Aged 6 to 24 Months

Growth Hormone in a Patient With a Dominant-Negative GHR Mutation

Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)

Impact of Pre-pregnancy Micronutrient Supplementation on Maternal and Child Outcomes

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ (ECOS Taiwan, Indonesia, Singapore)